ArticlebioRxiv : the preprint server for biology2026
Inflammaging mediates testosterone declines in men while maintaining high testosterone increases mortality risk.
Article in bioRxiv : the preprint server for biology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
Abstract
Later life is accompanied by testosterone declines alongside the development of chronic inflammation, termed inflammaging. A new theoretical model posits these processes are related through an energetic trade-off. As somatic damage accumulates, this should chronically activate the energetically costly inflammatory response. As an energy conserving response to promote cellular repair, testosterone production is expected to be suppressed. Consistent with this model, we find that markers of inflammaging, including IL-6 and GDF-15, mediate age-related testosterone declines in a large sample of male participants from the UK Biobank (n = 18,347, mean age 57 years, range 40-70). GDF-15, a marker of chronic inflammation and a key metabolic stress signaling protein, was the strongest predictor and mediator of testosterone declines. Further, individuals with high testosterone given their health and level of inflammation showed elevated mortality risk over follow up, consistent with a trade-off between maintenance and reproduction. Our results highlight the importance of considering energetic trade-offs to understand later life testosterone declines. They also highlight the importance of alleviating cellular damage that augments inflammaging and its down-stream hormonal effects. Finally, our study raises concern for exogenous testosterone therapies in the context of chronic inflammation, which could increase mortality risk.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.